2012 Fiscal Year Final Research Report
Regulation of regeneration, disease and carcinogenesis throughthe ON-OFF conversion of the cMet/HGF receptor.
Project/Area Number |
23790327
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
General medical chemistry
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Project Period (FY) |
2011 – 2012
|
Keywords | HGF / Met / 組織再生 / シグナル伝達 / シグナル伝達 |
Research Abstract |
Regulation mechanisms of the ON-OFF conversion of the HGF-cMetsignal had remained to be clarified. We found that phosphorylation of the cMet-Ser985was involved in suppression of the HGF-dependent cMet bioactivity through internalization of the cMet intracellularly from the cell surface. Moreover, we found that cMet exerts its biological activities only when they were dimer, and never exerts when monomer, even if strongly phosphorylated.
|
Research Products
(21 results)
-
-
-
[Journal Article] The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor2013
Author(s)
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, and Yano S
-
Journal Title
Int J Cancer
Volume: (in press)
DOI
Peer Reviewed
-
[Journal Article] HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells2013
Author(s)
Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, and Otsuji E
-
Journal Title
Int J Oncol
Volume: Vol. 42: no.2
Pages: 535-542
DOI
Peer Reviewed
-
[Journal Article] Combined therapy with mutantselective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer2012
Author(s)
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, and Yano S
-
Journal Title
Mol Cancer Ther
Volume: Vol. 11: no.10
Pages: 2149-2157
Peer Reviewed
-
[Journal Article] Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer2012
Author(s)
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, and Yano S
-
Journal Title
Am J Pathol
Volume: Vol. 181: no.3
Pages: 1034-1043
DOI
Peer Reviewed
-
[Journal Article] Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells2012
Author(s)
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, and Yano S
-
Journal Title
Clinical Cancer Research
Volume: Vol. 18: no.13
Pages: 3592-3602
DOI
Peer Reviewed
-
-
[Journal Article] Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer2012
Author(s)
Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, and Yano S
-
Journal Title
Clinical Cancer Research
Volume: Vol. 18
Pages: 1663-1671
DOI
Peer Reviewed
-
-
-
-
[Journal Article] NK4 Gene Expression Enhances 5-Fluorouracil -induced Apoptosis of Murine Colon Cancer Cells2011
Author(s)
Taiyoh H, Kubota T, Fujiwara H, Matsumura A, Murayama Y, Okamoto K, Ichikawa D, Ochiai T, Nakamura T, Matsumoto K, Nnakamura T, and Otsuji E
-
Journal Title
ANTICANCER RESEARCH
Volume: Vol. 31
Pages: 2217-2224
URL
Peer Reviewed
-
-
-
-
-
-
-
[Book] Advances in Cancer Therapy2011
Author(s)
Sakai K, Nakamura T, Suzuki Y, and Matsumoto K
Total Pages
313-333
Publisher
Significance, Mechanisms, and Progress of Anticancer Drugs Targeting HGF-Met
-